Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Although Novo was first to market with Wegovy and its sister ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.

CVS’s decision directly threatens a sizable portion of Zepbound’s addressable market. The potential impact of CVS's formulary decision regarding Zepbound may be somewhat limited. Lilly ...

The trial’s results, expected by June 2025, could significantly impact the company’s position in the diabetes treatment ... favoring Wegovy over Zepbound, may affect Eli Lilly’s market dynamics.

The entrance of more GLP-1 agonists into the market, especially generic ones, could eventually bring prices down. But until that happens, if you are interested in taking Ozempic, Zepbound or any ...